Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians

verfasst von: Pooja Malhotra, Mumtaz Anwar, Neha Nanda, Rakesh Kochhar, Jai Dev Wig, Kim Vaiphei, Safrun Mahmood

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The incidence of colorectal cancer (CRC) is increasing rapidly in Asian countries during the past few decades, but no comprehensive analysis has been done to find out the exact cause of this disease. In this study, we investigated the frequencies of mutations and expression pattern of K-ras, APC (adenomatosis polyposis coli) and p53 in tumor, adjoining and distant normal mucosa and to correlate these alterations with patients clinicopathological parameters as well as with the survival. Polymerase chain reaction (PCR)-restriction digestion was used to detect mutations in K-ras and PCR-SSCP (Single Strand Conformation Polymorphism) followed by DNA sequencing was used to detect mutations in APC and p53 genes. Immunohistochemistry was used to detect the expression pattern of K-ras, APC and p53 proteins. The frequencies of mutations of K-ras, APC and p53 in 30 tumor tissues samples were 26.7 %, 46.7 % and 20 %, respectively. Only 3.3 % of tumors contained mutations in all the three genes. The most common combination of mutation was APC and p53 whereas mutation in both p53 and K-ras were extremely rare. There was no association between the mutations and expression pattern of K-ras, APC and p53 (p > 0.05). In Indians, the frequency of alterations of K-ras and APC is similar as in Westerns, whereas the frequency of p53 mutation is slightly lower. The lack of multiple mutations in tumor specimens suggests that these genetic alterations might have independent influences on CRC development and there could be multiple alternative genetic pathways to CRC in our present study cohort.
Literatur
1.
Zurück zum Zitat Boyle P, Lagman J. ABC of colorectal cancer—epidemiology. Br Med J. 2000;321:805–8.CrossRef Boyle P, Lagman J. ABC of colorectal cancer—epidemiology. Br Med J. 2000;321:805–8.CrossRef
2.
Zurück zum Zitat Parkin DM, Muir CS, Whelan SL, Gao JT, Ferlay J, Powell J. Cancer Incidence in five continents, comparability and quality of data. Intl Agency Res Cancer Lyon France. 1992;120:45–173. Parkin DM, Muir CS, Whelan SL, Gao JT, Ferlay J, Powell J. Cancer Incidence in five continents, comparability and quality of data. Intl Agency Res Cancer Lyon France. 1992;120:45–173.
3.
Zurück zum Zitat Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.PubMedCrossRef Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.PubMedCrossRef
4.
Zurück zum Zitat Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525–32.PubMedCrossRef Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525–32.PubMedCrossRef
5.
Zurück zum Zitat Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRef Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRef
6.
Zurück zum Zitat Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.PubMedCrossRef Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.PubMedCrossRef
7.
8.
Zurück zum Zitat Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55–67.PubMedCrossRef Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55–67.PubMedCrossRef
9.
Zurück zum Zitat Bodmer WF, Bailey CJ, Bodmer J, Bussey H, Ellis A, Gorman P, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328:614–6.PubMedCrossRef Bodmer WF, Bailey CJ, Bodmer J, Bussey H, Ellis A, Gorman P, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328:614–6.PubMedCrossRef
10.
Zurück zum Zitat Nakamura Y. The role of the adenomatous polyposis coli (APC) gene in human cancers. Adv Cancer Res. 1993;62:65–87.PubMedCrossRef Nakamura Y. The role of the adenomatous polyposis coli (APC) gene in human cancers. Adv Cancer Res. 1993;62:65–87.PubMedCrossRef
11.
Zurück zum Zitat Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–6.PubMed Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–6.PubMed
12.
Zurück zum Zitat Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–22.PubMed Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–22.PubMed
13.
14.
Zurück zum Zitat Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2009;99(14):9433–8.CrossRef Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2009;99(14):9433–8.CrossRef
15.
Zurück zum Zitat Sriram PVJ, Kochhar R, Bhasin DK, Vaiphei K, Goenka MK, Singh K. Colonoscopic surveillance for synchronous lesions in colorectal carcinoma in north India. Eur J Cancer Supp. 1998;2(34):S16. Sriram PVJ, Kochhar R, Bhasin DK, Vaiphei K, Goenka MK, Singh K. Colonoscopic surveillance for synchronous lesions in colorectal carcinoma in north India. Eur J Cancer Supp. 1998;2(34):S16.
16.
Zurück zum Zitat Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001. p. 6.4–6.12. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001. p. 6.4–6.12.
17.
Zurück zum Zitat Ando M, Maruyama M, Oto M, Takemura K, Endo M, Yuasa Y. Higher frequency of point mutations in the c-k-ras2 gene in human colorectal adenomas with severe atypia than in carcinomas. Jpn J Cancer Res. 1991;82:245–9.PubMedCrossRef Ando M, Maruyama M, Oto M, Takemura K, Endo M, Yuasa Y. Higher frequency of point mutations in the c-k-ras2 gene in human colorectal adenomas with severe atypia than in carcinomas. Jpn J Cancer Res. 1991;82:245–9.PubMedCrossRef
18.
Zurück zum Zitat Poncin J, Mulkens J, Arends JW, De Goeij A. Optimizing the APC gene mutation analysis in archival colorectal tumor tissue. Diagn Mol Pathol. 1998;8:11–9.CrossRef Poncin J, Mulkens J, Arends JW, De Goeij A. Optimizing the APC gene mutation analysis in archival colorectal tumor tissue. Diagn Mol Pathol. 1998;8:11–9.CrossRef
19.
Zurück zum Zitat Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364–74.PubMed Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364–74.PubMed
20.
Zurück zum Zitat Hayashi K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl. 1991;1(1):34–8.PubMedCrossRef Hayashi K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl. 1991;1(1):34–8.PubMedCrossRef
21.
Zurück zum Zitat Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer. 1999;35:1986–2002.PubMedCrossRef Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer. 1999;35:1986–2002.PubMedCrossRef
22.
Zurück zum Zitat Jeon CH, Lee HI, Shin IH, Park JW. Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Color Dis. 2007;23(1):29–35.CrossRef Jeon CH, Lee HI, Shin IH, Park JW. Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Color Dis. 2007;23(1):29–35.CrossRef
23.
Zurück zum Zitat Konig EA, Koves I, Rasinariu A, Popp AR, Kusser WC, Soyonki K, et al. Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe. J Toxicol Environ Health A. 2001;62(5):333–47.PubMedCrossRef Konig EA, Koves I, Rasinariu A, Popp AR, Kusser WC, Soyonki K, et al. Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe. J Toxicol Environ Health A. 2001;62(5):333–47.PubMedCrossRef
24.
Zurück zum Zitat Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001;19(2):299–304.PubMed Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001;19(2):299–304.PubMed
25.
Zurück zum Zitat Brink M, Weijenberg MP, De Goeij AF, Schouten LJ, Koedijk FD, Roemen GM, et al. Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2004;25(9):1619–28.PubMedCrossRef Brink M, Weijenberg MP, De Goeij AF, Schouten LJ, Koedijk FD, Roemen GM, et al. Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2004;25(9):1619–28.PubMedCrossRef
26.
Zurück zum Zitat Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–6.PubMedCrossRef Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–6.PubMedCrossRef
27.
Zurück zum Zitat Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158(4):1517–24.PubMedCrossRef Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158(4):1517–24.PubMedCrossRef
28.
Zurück zum Zitat Van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene. 2002;21(23):3792–5.PubMedCrossRef Van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene. 2002;21(23):3792–5.PubMedCrossRef
29.
Zurück zum Zitat Onda M, Abe R, Tsuchiya A, Fukushima T, Ando Y, Yoshida T. K-ras and p53 gene mutations in colorectal cancer in 57 Japanese patients. Fukushima J Med Sci. 1997;43(1):29–39.PubMed Onda M, Abe R, Tsuchiya A, Fukushima T, Ando Y, Yoshida T. K-ras and p53 gene mutations in colorectal cancer in 57 Japanese patients. Fukushima J Med Sci. 1997;43(1):29–39.PubMed
30.
Zurück zum Zitat Pan ZZ, Wan DS, Chen G, Li LR, Lu ZH, Huang BJ. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol. 2004;10(24):3688–90.PubMed Pan ZZ, Wan DS, Chen G, Li LR, Lu ZH, Huang BJ. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol. 2004;10(24):3688–90.PubMed
31.
Zurück zum Zitat Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytomaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol. 2000;53(1):24–30.PubMedCrossRef Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytomaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol. 2000;53(1):24–30.PubMedCrossRef
32.
Zurück zum Zitat Luchtenborg M, Weijenberg MP, Roemen GM, de Bruine AP, van den Brandt PA, Lentjes MH, et al. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis. 2004;25(7):1219–26.PubMedCrossRef Luchtenborg M, Weijenberg MP, Roemen GM, de Bruine AP, van den Brandt PA, Lentjes MH, et al. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis. 2004;25(7):1219–26.PubMedCrossRef
33.
Zurück zum Zitat Kim JC, Koo KH, Lee DH, Roh SA, Kim HC, Yu CS, et al. Mutations at the APC exon 15 in the colorectal neoplastic tissues of serial array. Int J Color Dis. 2001;16(2):102–7.CrossRef Kim JC, Koo KH, Lee DH, Roh SA, Kim HC, Yu CS, et al. Mutations at the APC exon 15 in the colorectal neoplastic tissues of serial array. Int J Color Dis. 2001;16(2):102–7.CrossRef
34.
Zurück zum Zitat Yuan P, Sun MH, Zhang JS, Zhu XZ, Shi DR. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol. 2001;7(3):352–6.PubMed Yuan P, Sun MH, Zhang JS, Zhu XZ, Shi DR. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol. 2001;7(3):352–6.PubMed
35.
Zurück zum Zitat Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235–7.PubMedCrossRef Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235–7.PubMedCrossRef
36.
Zurück zum Zitat Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 2001;61(18):6656–9.PubMed Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 2001;61(18):6656–9.PubMed
37.
Zurück zum Zitat Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res. 2004;10(12):4015–21.PubMedCrossRef Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res. 2004;10(12):4015–21.PubMedCrossRef
38.
Zurück zum Zitat Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, et al. Alterations and correlations of the components in the Wntsignaling pathway and its target genes in breast cancer. Oncol Rep. 2005;14(6):1437–43.PubMed Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, et al. Alterations and correlations of the components in the Wntsignaling pathway and its target genes in breast cancer. Oncol Rep. 2005;14(6):1437–43.PubMed
39.
Zurück zum Zitat Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis. 2000;21(11):1935–40.PubMedCrossRef Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis. 2000;21(11):1935–40.PubMedCrossRef
40.
Zurück zum Zitat Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60(16):4366–71.PubMed Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60(16):4366–71.PubMed
41.
Zurück zum Zitat Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005;204(2):484–8.PubMedCrossRef Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005;204(2):484–8.PubMedCrossRef
42.
Zurück zum Zitat Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99(4):597–602.PubMedCrossRef Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99(4):597–602.PubMedCrossRef
43.
Zurück zum Zitat Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer. 2000;36(16):2053–60.PubMedCrossRef Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer. 2000;36(16):2053–60.PubMedCrossRef
44.
Zurück zum Zitat Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat. 2000;15(1):105–13.PubMedCrossRef Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat. 2000;15(1):105–13.PubMedCrossRef
45.
Zurück zum Zitat Soussi T, Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003;21(3):192–200.PubMedCrossRef Soussi T, Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003;21(3):192–200.PubMedCrossRef
46.
Zurück zum Zitat Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87(19):7555–9.PubMedCrossRef Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87(19):7555–9.PubMedCrossRef
47.
Zurück zum Zitat Tullo A, D'Erchia AM, Honda K, Mitry RR, Kelly MD, Habib NA, et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res. 1999;5(11):3523–8.PubMed Tullo A, D'Erchia AM, Honda K, Mitry RR, Kelly MD, Habib NA, et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res. 1999;5(11):3523–8.PubMed
48.
Zurück zum Zitat Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51.PubMedCrossRef Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51.PubMedCrossRef
49.
Zurück zum Zitat Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006;103(4):976–81.PubMedCrossRef Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006;103(4):976–81.PubMedCrossRef
50.
Zurück zum Zitat Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(3):434–44.PubMed Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(3):434–44.PubMed
51.
Zurück zum Zitat Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1996;27(10):1050–5.PubMedCrossRef Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1996;27(10):1050–5.PubMedCrossRef
52.
Zurück zum Zitat Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994;70(4):585–90.PubMedCrossRef Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994;70(4):585–90.PubMedCrossRef
53.
Zurück zum Zitat Cripps KJ, Purdie CA, Carder PJ, White S, Komine K, Bird CC, et al. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene. 1994;9(9):2739–43.PubMed Cripps KJ, Purdie CA, Carder PJ, White S, Komine K, Bird CC, et al. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene. 1994;9(9):2739–43.PubMed
54.
Zurück zum Zitat Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol. 1996;5(3):187–93.PubMedCrossRef Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol. 1996;5(3):187–93.PubMedCrossRef
55.
Zurück zum Zitat Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res. 1991;51(16):4436–42.PubMed Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res. 1991;51(16):4436–42.PubMed
56.
Zurück zum Zitat Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992;1(4):229–33.PubMedCrossRef Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992;1(4):229–33.PubMedCrossRef
57.
Zurück zum Zitat Andreyev HJ, Tilsed JV, Cunningham D, Sampson SA, Norman AR, Schneider HJ, et al. K-ras mutations in patients with early colorectal cancers. Gut. 1997;41(3):323–9.PubMedCrossRef Andreyev HJ, Tilsed JV, Cunningham D, Sampson SA, Norman AR, Schneider HJ, et al. K-ras mutations in patients with early colorectal cancers. Gut. 1997;41(3):323–9.PubMedCrossRef
58.
Zurück zum Zitat Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369–78.PubMed Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369–78.PubMed
59.
Zurück zum Zitat Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14(10):2696–701.PubMed Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14(10):2696–701.PubMed
60.
Zurück zum Zitat Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol. 2008;97:51–6.PubMedCrossRef Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol. 2008;97:51–6.PubMedCrossRef
Metadaten
Titel
Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians
verfasst von
Pooja Malhotra
Mumtaz Anwar
Neha Nanda
Rakesh Kochhar
Jai Dev Wig
Kim Vaiphei
Safrun Mahmood
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0734-y

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.